Nebenwirkungen · Xgeva
XGEVA 120 mg solution for injection XGEVA 120 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-124653 · Präparat HOS-095905
In the primary treatment phases of three phase III active-controlled clinical trials in patients with advanced malignancies involving bone, ONJ was confirmed in 1.8% of patients treated with XGEVA (median exposure of 12.0 months; range: 0.1 – 40.5) and 1.3% of patients treated with zoledronic acid. Clinical characteristics of these cases were similar between treatment groups. Among patients with confirmed ONJ, most (81% in both treatment groups) had a history of tooth extraction, poor oral hygiene, and/or use of a dental appliance. Most patients were receiving or had received chemotherapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-30T11:39:12Z · SHA-256 128fc1cc30bb902fd35b573513956c486b321d921f1c9f82cbb86938b613ea4c · Passage 8d83b0de5aa0c5251c5f0e37e5f9505963f28d4dcdb629884fdcc3878b2b7e37 · Zeichen 8129–8725 im Abschnitt